Dr. Alexandra Legge on the Clinical Assessment of Suspected Connective Tissue Disease

Few referrals cause more uncertainty in primary care than the patient with fatigue, joint pain, and a positive ANA. In a recent Virtual Hallway webinar — part one of a two-part series on early SLE diagnosis — Dr. Alexandra Legge, rheumatologist, Director of the Dalhousie Lupus Clinic, and chair of the SLICC World Lupus Committee, walked through how careful clinical assessment can separate true connective tissue disease from its far more common mimics. Here are the essential takeaways from her expert session and why you should catch the full recording.

Connective Tissue Disease vs. Heritable Connective Tissue Disorders

Dr. Legge began by clearing up one of the most common sources of confusion in referrals. When rheumatologists say “connective tissue disease” (CTD) — increasingly called systemic autoimmune rheumatic disease, or SARD — they mean five autoimmune, inflammatory conditions: SLE, primary Sjögren’s syndrome, mixed connective tissue disease (MCTD), inflammatory myositis, and systemic sclerosis. These are ANA-associated, multi-system diseases treated with immunomodulatory therapy.

Heritable disorders of connective tissue — like Marfan syndrome and Ehlers-Danlos syndrome — are a completely separate, genetic, non-inflammatory group. Hypermobile EDS is the most common, is a clinical diagnosis any practitioner can make, and has no role for immunomodulatory therapy. In Dr. Legge’s experience, rheumatology consultation adds little value for hypermobility unless inflammatory arthritis needs to be ruled out.

Making (or Doubting) a Lupus Diagnosis

SLE is rarer than most patients suspect — roughly 1 in 2,000 Canadians, affecting women 8–9 times more often than men, typically starting in the teens or early adulthood. Dr. Legge stressed that a lupus diagnosis always requires both clinical features and immunologic abnormalities — never one alone:

• Helpful clinical clues: fever and other constitutional symptoms (drenching night sweats, weight loss, lymphadenopathy), symmetric small-joint polyarthritis, serositis, dramatic neuropsychiatric events like psychosis or seizures, and characteristic mucocutaneous findings.
• Not helpful: fatigue and brain fog — common in lupus but highly non-specific and poor at differentiating it from fibromyalgia.
• Lab clues: leukopenia and lymphopenia, thrombocytopenia, autoimmune hemolytic anemia, low C3/C4, lupus-specific antibodies (dsDNA, Smith), and antiphospholipid antibodies. In every suspected case, check creatinine, urinalysis with microscopy, and a spot urine protein-to-creatinine ratio to rule out renal involvement.

Reading the Face: Malar Rash vs. Rosacea

Cutaneous involvement occurs in about 80% of SLE, but cutaneous lupus in isolation is 2–3 times more common than systemic disease. Key pearls:

• The classic malar rash — fixed, raised, photosensitive plaques sparing the nasolabial folds — is almost universally associated with systemic disease and a positive ANA. A facial eruption with a negative ANA should prompt an alternative diagnosis.
• The most common mimic by far is rosacea, affecting roughly 5% of the population. Transient flushing lasting minutes to hours, pustules, and non-sun triggers (heat, alcohol, stress) all point away from lupus.
• In discoid lupus, check the conchal bowl of the inner ear — a favourite tip from her dermatology colleagues — and remember only a small minority ever develop systemic disease.

Raynaud’s: What Counts and What Doesn’t

Raynaud’s phenomenon can accompany any SARD, but primary Raynaud’s is far more common, affecting up to 5% of the population. Diagnosis hinges on white discoloration with sharp demarcation — not pain or paresthesias in the cold. Red flags for a secondary cause include onset later in life (especially in men), thumb involvement, digital pits or ulcers, and abnormal nail fold capillaries. Most primary Raynaud’s is managed with warmth, trigger avoidance, and smoking cessation; calcium channel blockers like nifedipine XL or amlodipine are first-line when pharmacotherapy is needed.

Fibromyalgia: Rule It In, Not Just Out

Dr. Legge closed with a strong message: fibromyalgia — the most common cause of chronic widespread MSK pain, affecting up to 6% of the population — is not a diagnosis of exclusion but a distinct clinical syndrome you can rule in. Look for widespread articular and non-articular pain, morning stiffness that never fully resolves, subjective swelling without objective synovitis, and post-exertional malaise. The SPACE acronym captures the accompanying non-pain features: Sleep disturbance, Pain elsewhere (chronic overlapping pain conditions), Affective symptoms, Cognitive symptoms, and Energy (profound fatigue). If the picture fits fibromyalgia, autoimmune serologies like ANA and rheumatoid factor are not required.

The Takeaway

Clinical assessment drives everything. Pre-test probability — built from a careful history and physical exam — should determine whether ANA testing is ordered at all, because indiscriminate testing generates minor abnormalities that fuel unnecessary referrals, healthcare utilization, and patient anxiety.

Watch the Full Lecture

Ready to sharpen your approach to the “is it lupus?” question? Watch the full session with Dr. Legge on Virtual Hallway to:

• Work through her two contrasting clinical cases from presentation to diagnosis.
• Earn MainPro+ credits.
• Sign up for free at virtualhallway.ca

Then catch Part 2 of the series, where Dr. Julie Mongeau tackles the laboratory workup. Log in, learn, and bring more confidence to your next connective tissue disease workup.